Ireland
--:--IST
Priya Life Science Sponsor trial record
Sponsor · clinical trials

Groupe Francais De Pneumo-Cancerologie clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our France register with Groupe Francais De Pneumo-Cancerologie as lead sponsor. Synced 16 Nov 2026
4Current trials
3Recruiting now
0Drugs in these trials
1Trial register
At a glance

Groupe Francais De Pneumo-Cancerologie is the lead sponsor of 4 current clinical trials in our France register. 3 are recruiting patients now. The most common phase is Not applicable. The most-studied condition is Non-small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting375%
  • Active, closed125%

Trials by phase

  • Not applicable250%
  • Phase 2125%
  • Observational125%
01

Clinical trials sponsored by Groupe Francais De Pneumo-Cancerologie

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib
NCT06620835 · ClinicalTrials.gov ↗ · NSCLC
Phase 2 Recruiting 2025-06 France
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
NCT05122806 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive
Not applicable Recruiting 2021-09 France
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion
NCT06247826 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation
Not applicable Recruiting 2024-01 France
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
NCT05049044 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Observational Active, closed 2020-12 France

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Conditions in Groupe Francais De Pneumo-Cancerologie trials

5 conditions
Non-small Cell Lung Cancer2NSCLC1Non-Small Cell Lung Cancer1ALK Gene Rearrangement Positive1EGFR Exon 20 Insertion Mutation1
03

By trial register

RegisterTrialsRecruiting
Clinical trials in France43

A trial with sites in more than one country appears in each of those registers.

04

Other sponsors in Non-small Cell Lung Cancer

SponsorTrials
AstraZeneca15
Sichuan Baili Pharmaceutical15
Merck Sharp & Dohme10
Bristol-Myers Squibb6
Daiichi Sankyo6
Hoffmann-La Roche6
Shanghai Chest Hospital5
Sichuan Kelun-Biotech Biopharmaceutical5
Shanghai Pulmonary Hospital, Shanghai, China4
Hunan Province Tumor Hospital4

Sponsors with the most current trials registered for this condition.

05

Questions about Groupe Francais De Pneumo-Cancerologie trials

How many clinical trials does Groupe Francais De Pneumo-Cancerologie sponsor?

Groupe Francais De Pneumo-Cancerologie is the lead sponsor of 4 current trials on ClinicalTrials.gov in our France register, as of the registry sync on 16 November 2026. Completed and withdrawn studies are not counted.

Are Groupe Francais De Pneumo-Cancerologie trials recruiting?

Yes. 3 of its 4 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 16 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.